Under the terms of the contract, the state will pay a fixed dollar amount to AbbVie for an unlimited supply of hepatitis C drugs.
The contract is part of the state’s plan to eliminate hepatitis C by 2030.
Last month, the state of Louisiana struck a deal with a Gilead Sciences subsidiary to supply hepatitis C medication under a subscription-style payment model.
Both Washington and Louisiana plan to start their programs this summer.
More articles on pharmacy:
10 hospitals seeking pharmacy leaders
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.